Phage Therapy: Future Inquiries.

Area of Science:

• Microbiology
• Infectious Diseases
• Biotechnology

Background:

• Phage therapy, using bacteriophages as antibacterial agents, was pioneered in the early 20th century.
• Interest in phage therapy resurged in the mid-1980s due to increasing antibiotic resistance.
• Limited understanding of phage biology and the availability of antibiotics previously deprioritized phage therapy in Western medicine.

Purpose of the Study:

• To review the historical context and current resurgence of interest in phage therapy.
• To highlight the potential of bacteriophages as therapeutic agents, particularly in light of antibiotic resistance.
• To emphasize the critical need for rigorous in vitro and in vivo studies to support clinical applications.

Main Methods:

• Review of historical scientific literature on bacteriophage therapy.
• Analysis of current trends in molecular biology and phage-host interactions.
• Examination of regulatory considerations and the status of clinical trials.

Main Results:

• Bacteriophages (phages) are viruses that infect bacteria, offering a potential alternative to antibiotics.
• Advances in molecular biology enhance understanding of phage-host specificity, enabling personalized treatment strategies.
• The U.S. FDA acknowledges bacteriophages' potential, evidenced by their use as food additives.

Conclusions:

• Phage therapy presents a promising avenue for combating antibiotic-resistant bacterial infections.
• Further robust clinical research is imperative to validate phage therapy's safety and effectiveness.
• Meeting regulatory standards through well-designed studies is crucial for integrating phage therapy into healthcare.